Literature DB >> 7992464

Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.

M J Stassar1, P D Vegt, P A Steerenberg, A P van der Meijden, H D Meiring, M Dessens-Kroon, H G Geertzen, W den Otter.   

Abstract

Because recent investigations showed that the use of isoniazid (INH) severely impaired the local immune reaction to intravesical bacillus Calmette-Guérin (BCG) in the bladder of guinea pigs, in this study the effect of INH in man has been investigated. Patients were treated with BCG with or without oral INH. The concentration of free INH in most urine samples of patients treated with BCG/INH was much higher (mean 38.0 +/- 60.9 micrograms INH/ml) than the minimal inhibitory concentration (MIC; 0.1 microgram INH/ml), suggesting at least a bacteriostatic potential of the INH present. However, in vitro studies showed that these urinary concentrations of INH did not kill BCG organisms effectively, even at a concentration of 150 micrograms/ml for 24 h. After the fifth and sixth BCG instillations a significant increase in the concentration of cytokines (IL2, IL6, IL8 and TNFa), IgG and IgA antibodies to BCG and the number of leukocytes in urine was observed. The leukocytes mainly consisted of granulocytes, besides monocytes/macrophages and, in lower amounts, T- and B-lymphocytes and natural killer (NK) cells. The absolute number of granulocytes and the concentration of IgG antibodies after BCG instillation were significantly suppressed by INH, whereas INH appeared to have no effect on the urinary cytokine and IgA antibody concentrations or the total number and phenotype of the leukocytes present. In conclusion, the results of this study indicate that INH does not impair the local immunological stimulation after BCG instillation in man as severely as was observed in the guinea pig and it may be expected that INH does not impair the antitumor efficacy of BCG.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7992464     DOI: 10.1007/BF00571847

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  26 in total

1.  Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma.

Authors:  A Böhle; C Nowc; A J Ulmer; J Musehold; J Gerdes; A G Hofstetter; H D Flad
Journal:  Cytokine       Date:  1990-05       Impact factor: 3.861

2.  Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guérin administration.

Authors:  M Bettex-Galland; U E Studer; A Walz; B Dewald; M Baggiolini
Journal:  Eur Urol       Date:  1991       Impact factor: 20.096

3.  Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.

Authors:  E C de Boer; W H de Jong; A P van der Meijden; P A Steerenberg; F Witjes; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1991

4.  Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.

Authors:  A Böhle; J Gerdes; A J Ulmer; A G Hofstetter; H D Flad
Journal:  J Urol       Date:  1990-07       Impact factor: 7.450

5.  Towards an understanding of the mode of action of Bacillus Calmette-Guérin-therapy in bladder cancer treatment, especially with regard to the role of fibronectin.

Authors:  E van der Sloot; S Kuster; A Böhle; J Braun; W G Wood
Journal:  Eur J Clin Chem Clin Biochem       Date:  1992-09

6.  Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin.

Authors:  W H De Jong; E C De Boer; A P Van der Meijden; P Vegt; P A Steerenberg; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig.

Authors:  L C De Boer; P A Steerenberg; P M Van der Meijden; B Van Klingeren; W H De Jong; A Elgersma; F M Debruyne; E J Ruitenberg
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

8.  Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.

Authors:  E O Haaff; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

9.  HLA-DR expression by high grade superficial bladder cancer treated with BCG.

Authors:  S Prescott; K James; A Busuttil; T B Hargreave; G D Chisholm; J F Smyth
Journal:  Br J Urol       Date:  1989-03

Review 10.  Non specific immunotherapy with B.C.G. in superficial bladder cancer: an overview.

Authors:  A P Van der Meijden
Journal:  In Vivo       Date:  1991 Nov-Dec       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.